Integrative genomic analyses of secreted protein acidic and rich in cysteine and its role in cancer prediction

Molecular Medicine Reports

Volumn 10, Issue 3, 2014, Pages 1461-1468

  Wang, Bo ^a   Chen, Kai ^a   Xu, Wenming ^a   Chen, Di ^a   Tang, Wei ^a   Xia, Tian Song ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Comparative genomics; Meta analysis; Prognosis; SPARC

Indexed keywords

OSTEONECTIN; SPARC PROTEIN, HUMAN;

ADIPOCYTE; AMPHIBIA; ARTICLE; BIRD; BLADDER CANCER; BLOOD; BONE MARROW; BRAIN; BREAST CANCER; CANCER PROGNOSIS; CEREBELLUM; COLON; COLORECTAL CANCER; ESOPHAGUS CANCER; FISH; GENE EXPRESSION PROFILING; GENOME ANALYSIS; GENOMICS; HEAD AND NECK CANCER; HEART; HUMAN; INTESTINE; KIDNEY; LIVER; LUNG CANCER; LYMPH NODE; MAMMAL; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY; OVARY CANCER; PANCREAS; PLACENTA; PREDICTION; PROSTATE; PROTEOMICS; RETINA; SALIVARY GLAND; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; SKIN; SKIN CANCER; SMOOTH MUSCLE; SPINAL CORD; THYMUS; THYROID GLAND; UTERINE CERVIX; UTERUS; VERTEBRATE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; GENOME; META ANALYSIS (TOPIC); METABOLISM; NEOPLASM; PROCEDURES; PROGNOSIS;

AMPHIBIANS; ANIMALS; BIRDS; FISHES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; GENOMICS; HUMANS; MAMMALS; META-ANALYSIS AS TOPIC; NEOPLASMS; OSTEONECTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEOMICS;

EID: 84905447555     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2339     Document Type: Article

References (79)

1. Bradshaw AD, Graves DC, Motamed K and Sage EH: SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc Natl Acad Sci USA 100: 6045-6050, 2003. (Pubitemid 36576928)
2. Schwartz RC, Young MF and Tsipouras P: Two RFLPs in the 5′ end of the human osteonectin (ON) gene. Nucleic Acids Res 16: 9076, 1988.
3. Mayer U, Aumailley M, Mann K, Timpl R and Engel J: Calcium-dependent binding of basement membrane protein BM-40 (osteonectin, SPARC) to basement membrane collagen type IV. Eur J Biochem 198: 141-150, 1991.
4. Bradshaw AD: The role of SPARC in extracellular matrix assembly. J Cell Commun Signal 3: 239-246, 2009.
5. Rivera LB and Brekken RA: SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-beta1 activity. J Cell Biol 193: 1305-1319, 2011.
6. Choi BD, Yun SH, Jeong SJ, et al: Expression of thymosin beta4 in odontoblasts during mouse tooth development. Int J Mol Med 29: 841-847, 2012.
7. Nonogaki S, Campos HG, Butugan O, et al: Markers of vascular differentiation, proliferation and tissue remodeling in juvenile nasopharyngeal angiofibromas. Exp Ther Med 1: 921-926, 2010.
8. Prenzel KL, Warnecke-Eberz U, Xi H, et al: Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncol Rep 15: 1397-1401, 2006.
9. Rodriguez-Jiménez FJ, Caldés T, Iniesta P, Vidart JA, Garcia-Asenjo JL and Benito M: Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. Oncol Rep 17: 1301-1307, 2007.
10. Kunigal S, Gondi CS, Gujrati M, et al: SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 29: 1349-1357, 2006.
11. Seno T, Harada H, Kohno S, Teraoka M, Inoue A and Ohnishi T: Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 34: 707-715, 2009.
12. Sailaja GS, Bhoopathi P, Gorantla B, et al: The secreted protein acidic and rich in cysteine (SPARC) induces endoplasmic reticulum stress leading to autophagy-mediated apoptosis neuroblastoma. Int J Oncol 42: 188-196, 2013.
13. Liu H, Xu Y, Chen Y, et al: RNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells. Oncol Lett 2: 985-990, 2011.
14. Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 38: 1197-1217, 2011.
15. Zhang JL, Chen GW, Liu YC, et al: Secreted protein acidic and rich in cysteine (SPARC) suppresses angiogenesis by down-regulating the expression of VEGF and MMP-7 in gastric cancer. PLoS One 7: e44618, 2012.
16. Arnold SA, Rivera LB, Carbon JG, et al: Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation. PLoS One 7: e31384, 2012.
17. Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA and Theodorescu D: Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest 123: 751-766, 2013.
18. Yang L, Luo Y and Wei J: Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncol Rep 24: 571-577, 2010.
19. Yang L, Luo Y, Wei J and He S: Integrative genomic analyses on IL28RA, the common receptor of interferon-lambda1, -lambda2 and -lambda3. Int J Mol Med 25: 807-812, 2010.
20. Yang L, Wei J and He S: Integrative genomic analyses on interferon-lambdas and their roles in cancer prediction. Int J Mol Med 25: 299-304, 2010.
21. Yu H, Yuan J, Xiao C and Qin Y: Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer. Int J Mol Med 31: 1248-1254, 2013.
22. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F and Higgins DG: The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882, 1997. (Pubitemid 28022245)
23. Guindon S, Lethiec F, Duroux P and Gascuel O: PHYML Online - a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res 33: W557-W559, 2005. (Pubitemid 44529983)
24. Kumar S, Tamura K and Nei M: MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5: 150-163, 2004.
25. Yang Z: PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci 13: 555-556, 1997.
26. Yang Z, Nielsen R, Goldman N and Pedersen AM: Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155: 431-449, 2000. (Pubitemid 30257141)
27. Katoh Y and Katoh M: Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol 35: 187-192, 2009.
28. Katoh M and Katoh M: Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling. Int J Mol Med 24: 247-251, 2009.
29. Katoh M and Katoh M: Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 23: 763-769, 2009.
30. Katoh M and Katoh M: Transcriptional regulation of WNT2B based on the balance of Hedgehog, Notch, BMP and WNT signals. Int J Oncol 34: 1411-1415, 2009.
31. Chalifa-Caspi V, Yanai I, Ophir R, et al: GeneAnnot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. Bioinformatics 20: 1457-1458, 2004. (Pubitemid 38931417)
32. Parkinson H, Sarkans U, Shojatalab M, et al: ArrayExpress - a public repository for microarray gene expression data at the EBI. Nucleic Acids Res 33: D553-D555, 2005. (Pubitemid 40207935)
33. Kolker E, Higdon R, Morgan P, et al: SPIRE: Systematic protein investigative research environment. J Proteomics 75: 122-126, 2011.
34. Kolker E, Higdon R, Haynes W, et al: MOPED: Model Organism Protein Expression Database. Nucleic Acids Res 40: D1093-D1099, 2012.
35. Mizuno H, Kitada K, Nakai K and Sarai A: PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2: 18, 2009.
36. Metzeler KH, Hummel M, Bloomfield CD, et al: An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112: 4193-4201, 2008.
37. Hummel M, Bentink S, Berger H, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419-2430, 2006. (Pubitemid 43855045)
38. Jardin F, Jais JP, Molina TJ, et al: Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 116: 1092-1104, 2010.
39. Schmidt M, Böhm D, von Torne C, et al: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413, 2008.
40. Chin K, DeVries S, Fridlyand J, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541, 2006. (Pubitemid 44854748)
41. Miller LD, Smeds J, George J, et al: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550-13555, 2005. (Pubitemid 41420886)
42. Ivshina AV, George J, Senko O, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301, 2006. (Pubitemid 44799747)
43. Smith JJ, Deane NG, Wu F, et al: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138: 958-968, 2010.
44. Jorissen RN, Gibbs P, Christie M, et al: Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res 15: 7642-7651, 2009.
45. Laurent C, Valet F, Planque N, et al: High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res 71: 666-674, 2011.
46. Okayama H, Kohno T, Ishii Y, et al: Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 72: 100-111, 2012.
47. Lee ES, Son DS, Kim SH, et al: Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 14: 7397-7404, 2008.
48. Tothill RW, Tinker AV, George J, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208, 2008.
49. Bonome T, Levine DA, Shih J, et al: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486, 2008.
50. Sboner A, Demichelis F, Calza S, et al: Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 3: 8, 2010.
51. McCurdy SM, Dai Q, Zhang J, et al: SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 301: H497-H505, 2011.
52. Cheng L, Sage EH and Yan Q: SPARC fusion protein induces cellular adhesive signaling. PLoS One 8: e53202, 2013.
53. Nakamura K, Nakano S, Miyoshi T, Yamanouchi K, Matsuwaki T and Nishihara M: Age-related resistance of skeletal muscle-derived progenitor cells to SPARC may explain a shift from myogenesis to adipogenesis. Aging (Albany NY) 4: 40-48, 2012.
54. Pataquiva-Mateus AY, Wu HC, Lucchesi C, Ferraz MP, Monteiro FJ and Spector M: Supplementation of collagen scaffolds with SPARC to facilitate mineralization. J Biomed Mater Res B Appl Biomater 100: 862-870, 2012.
55. Li B, Li F, Chi L, Zhang L and Zhu S: The expression of SPARC in human intracranial aneurysms and its relationship with MMP-2/-9. PLoS One 8: e58490, 2013.
56. Seet LF, Tong L, Su R and Wong TT: Involvement of SPARC and MMP-3 in the pathogenesis of human pterygium. Invest Ophthalmol Vis Sci 53: 587-595, 2012.
57. Patterson J and Hubbell JA: SPARC-derived protease substrates to enhance the plasmin sensitivity of molecularly engineered PEG hydrogels. Biomaterials 32: 1301-1310, 2011.
58. Weaver MS, Sage EH and Yan Q: Absence of SPARC in lens epithelial cells results in altered adhesion and extracellular matrix production in vitro. J Cell Biochem 97: 423-432, 2006. (Pubitemid 43167155)
59. Lin ZY and Chuang WL: Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomed Pharmacother 66: 454-458, 2012.
60. Zhang Y, Yang B, Du Z, et al: Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication. World J Gastroenterol 18: 2043-2052, 2012.
61. Xue LY, Zou SM, Zheng S, et al: Expressions of the gamma2 chain of laminin-5 and secreted protein acidic and rich in cysteine in esophageal squamous cell carcinoma and their relation to prognosis. Chin J Cancer 30: 69-78, 2011.
62. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML and Martin GR: Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26: 99-105, 1981. (Pubitemid 12229368)
63. Mason IJ, Murphy D, Münke M, Francke U, Elliott RW and Hogan BL: Developmental and transformation-sensitive expression of the Sparc gene on mouse chromosome 11. EMBO J 5: 1831-1837, 1986.
64. Huynh MH, Sodek K, Lee H and Ringuette M: Interaction between SPARC and tubulin in Xenopus. Cell Tissue Res 317: 313-317, 2004. (Pubitemid 39222950)
65. Sage H, Decker J, Funk S and Chow M: SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation. J Mol Cell Cardiol 21 (Suppl 1): 13-22, 1989.
66. Leboy PS, Shapiro IM, Uschmann BD, Oshima O and Lin D: Gene expression in mineralizing chick epiphyseal cartilage. J Biol Chem 263: 8515-8520, 1988.
67. Aeschlimann D, Kaupp O and Paulsson M: Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: identification of osteonectin as a major glutaminyl substrate. J Cell Biol 129: 881-892, 1995.
68. Breton-Gorius J, Clezardin P, Guichard J, et al: Localization of platelet osteonectin at the internal face of the alpha-granule membranes in platelets and megakaryocytes. Blood 79: 936-941, 1992.
69. Komatsubara I, Murakami T, Kusachi S, et al: Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc Pathol 12: 186-194, 2003. (Pubitemid 36765492)
70. Yin F, Liu X, Li D, Wang Q, Zhang W and Li L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer. Int J Oncol 42: 1305-1316, 2013.
71. He Q, Wei J, Zhang J, et al: Aberrant methylation of secreted protein, acidic and rich in cysteine in human laryngeal and hypopharyngeal carcinoma. Oncol Lett 2: 725-729, 2011.
72. Chen D, Yang K, Mei J, Zhang G, Lv X and Xiang L: Screening the pathogenic genes and pathways related to DMBA (7,12-dimethylbenz[a]anthracene)- induced transformation of hamster oral mucosa from precancerous lesions to squamous cell carcinoma. Oncol Lett 2: 637-642, 2011.
73. Suhr ML, Dysvik B, Bruland O, et al: Gene expression profile of oral squamous cell carcinomas from Sri Lankan betel quid users. Oncol Rep 18: 1061-1075, 2007.
74. Gagliano N, Costa F, Cossetti C, et al: Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. Oncol Rep 22: 1349-1356, 2009.
75. Zhu XC, Dong QZ, Zhang XF, et al: microRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma. Int J Mol Med 30: 1321-1326, 2012.
76. Ylipää A, Yli-Harja O, Zhang W and Nykter M: A systems biological approach to identify key transcription factors and their genomic neighborhoods in human sarcomas. Chin J Cancer 30: 27-40, 2011.
77. Ren D, Wang M, Guo W, et al: Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR-145. Int J Oncol 42: 1473-1481, 2013.
78. Abou-El-Ardat K, Derradji H, de Vos W, et al: Response to low-dose X-irradiation is p53-dependent in a papillary thyroid carcinoma model system. Int J Oncol 39: 1429-1441, 2011.
79. Stefancikova L, Moulis M, Fabian P, et al: Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Int J Oncol 39: 1413-1420, 2011.